VYGR
Voyager Therapeutics, Inc.$3.79+0.04 (+0.93%)Prev Close$3.76·MCap$224.1M·P/E—·Vol187.0K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
12
$360.9K
◆
Net Activity
Net Seller
$360.9K
●
Active Insiders
5
last 12 mo
Over the past 12 months, insider activity at Voyager Therapeutics, Inc. (VYGR) has been exclusively selling, with 0 insider purchases totaling $0.00 and 12 insider sales totaling $360.9K. The most recent insider transaction was by Carter Todd Alfred (officer: Chief Scientific Officer), who sold $15.7K worth of shares on Feb 26, 2026. Voyager Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $224.1M.
VYGR Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | Carter Todd Alfred | officer: Chief Scientific Officer | Sell | 4,174 | $3.76 | $15.7K | 145,718 |
| Feb 26, 2026 | Jorgensen Nathan D. | officer: Chief Financial Officer | Sell | 4,668 | $3.77 | $17.6K | 151,416 |
| Feb 26, 2026 | Sandrock Alfred | director, officer: President and CEO | Sell | 14,197 | $3.79 | $53.8K | 484,060 |
| Feb 26, 2026 | Swartz Robin | officer: COO & CBO | Sell | 6,458 | $3.77 | $24.3K | 199,738 |
| Feb 18, 2026 | Carter Todd Alfred | Chief Scientific Officer | Sell | 3,301 | $3.44 | $11.4K | 0 |
| Feb 18, 2026 | Sandrock Alfred | President and CEO | Sell | 11,732 | $3.41 | $40.0K | 0 |
| Feb 18, 2026 | Swartz Robin | COO & CBO | Sell | 3,882 | $3.44 | $13.4K | 0 |
| Feb 11, 2026 | Carter Todd Alfred | officer: Chief Scientific Officer | Sell | 3,525 | $3.85 | $13.6K | 153,193 |
| Feb 11, 2026 | Sandrock Alfred | director, officer: President and CEO | Sell | 12,192 | $3.78 | $46.1K | 509,989 |
| Feb 11, 2026 | Swartz Robin | officer: COO & CBO | Sell | 4,569 | $3.85 | $17.6K | 210,078 |
| Oct 7, 2025 | Jorgensen Nathan D. | Chief Financial Officer | Sell | 7,666 | $4.78 | $36.6K | 123,834 |
| Aug 20, 2025 | Ferguson Toby | Chief Medical Officer | Sell | 19,000 | $3.73 | $70.9K | 138,914 |
| Apr 4, 2025 | Ferguson Toby | Chief Medical Officer | Sell | 10,086 | $3.43 | $34.6K | 157,914 |
| Apr 4, 2025 | Sandrock Alfred | President and CEO | Sell | 10,885 | $3.43 | $37.3K | 430,931 |
| Feb 24, 2025 | Carter Todd Alfred | Chief Scientific Officer | Sell | 3,305 | $4.26 | $14.1K | 77,718 |
| Feb 24, 2025 | Sandrock Alfred | President and CEO | Sell | 11,702 | $4.24 | $49.6K | 296,816 |
| Feb 24, 2025 | Swartz Robin | COO & CBO | Sell | 3,894 | $4.25 | $16.5K | 98,397 |
| Feb 12, 2025 | Carter Todd Alfred | Chief Scientific Officer | Sell | 5,413 | $4.45 | $24.1K | 81,023 |
| Feb 12, 2025 | Fahey Sandell Jacquelyn | Chief Legal Officer | Sell | 4,358 | $4.45 | $19.4K | 81,643 |
| Feb 12, 2025 | Sandrock Alfred | President & CEO | Sell | 16,644 | $4.45 | $74.1K | 308,518 |
| Feb 12, 2025 | Swartz Robin | COO & CBO | Sell | 6,950 | $4.45 | $30.9K | 102,291 |
| Jan 15, 2025 | Carter Todd Alfred | Chief Scientific Officer | Sell | 1,191 | $5.13 | $6.1K | 86,436 |
| Jan 15, 2025 | Swartz Robin | COO & CBO | Sell | 3,087 | $5.09 | $15.7K | 109,241 |
| Dec 26, 2024 | Swartz Robin | COO&CBO | Sell | 6,500 | $5.65 | $36.7K | 112,328 |
| Oct 3, 2024 | Fahey Sandell Jacquelyn | Chief Legal Officer | Sell | 5,999 | $5.82 | $34.9K | 86,001 |
| Apr 3, 2024 | Sandrock Alfred | President and CEO | Sell | 12,115 | $9.86 | $119.5K | 322,839 |
| Apr 3, 2024 | Swartz Robin | Chief Operating Officer | Sell | 1,357 | $9.88 | $13.4K | 117,004 |
| Feb 22, 2024 | Carter Todd Alfred | Chief Scientific Officer | Sell | 3,967 | $7.50 | $29.8K | 90,992 |
| Feb 22, 2024 | PFREUNDSCHUH PETER P. | Chief Financial Officer | Sell | 3,764 | $7.46 | $28.1K | 175,669 |
| Feb 22, 2024 | Sandrock Alfred | President and CEO | Sell | 13,033 | $7.46 | $97.2K | 334,954 |
| Feb 22, 2024 | Swartz Robin | Chief Operating Officer | Sell | 3,966 | $7.45 | $29.5K | 118,361 |
| Jan 19, 2024 | Carter Todd Alfred | Chief Scientific Officer | Sell | 1,266 | $7.18 | $9.1K | 53,094 |
| Jan 19, 2024 | Swartz Robin | Chief Operating Officer | Sell | 2,543 | $7.15 | $18.2K | 72,327 |
| Oct 5, 2023 | PFREUNDSCHUH PETER P. | Chief Financial Officer | Sell | 13,567 | $6.99 | $94.8K | 149,433 |
| Sep 18, 2023 | Carter Todd Alfred | Chief Scientific Officer | Sell | 10,500 | $8.16 | $85.7K | 54,360 |
| Jul 10, 2023 | Carter Todd Alfred | Chief Scientific Officer | Sell | 5,500 | $10.80 | $59.4K | 59,860 |
| Jul 5, 2023 | Carter Todd Alfred | Chief Scientific Officer | Sell | 5,000 | $11.41 | $57.0K | 65,360 |
| Apr 5, 2023 | Sandrock Alfred | President and CEO | Sell | 7,437 | $7.83 | $58.2K | 214,618 |
| Apr 5, 2023 | Swartz Robin | Chief Operating Officer | Sell | 1,259 | $7.83 | $9.9K | 71,617 |
| Mar 22, 2023 | Carter Todd Alfred | Chief Scientific Officer | Sell | 2,193 | $7.76 | $17.0K | 65,360 |
| Mar 22, 2023 | Hesslein Robert W. | Senior VP & General Counsel | Sell | 4,410 | $7.76 | $34.2K | 102,200 |
| Mar 22, 2023 | Swartz Robin | Chief Operating Officer | Sell | 3,654 | $7.76 | $28.4K | 72,876 |
| Mar 17, 2023 | Swartz Robin | Chief Operating Officer | Sell | 15,373 | $8.20 | $126.1K | 76,530 |
| Feb 22, 2023 | Carter Todd Alfred | Chief Scientific Officer | Sell | 738 | $7.45 | $5.5K | 67,553 |
| Feb 22, 2023 | Hesslein Robert W. | Senior VP & General Counsel | Sell | 3,297 | $7.45 | $24.6K | 106,610 |
| Feb 15, 2023 | Carter Todd Alfred | Chief Scientific Officer | Sell | 797 | $7.67 | $6.1K | 34,291 |
| Feb 15, 2023 | Hesslein Robert W. | Senior VP & General Counsel | Sell | 2,868 | $7.67 | $22.0K | 109,907 |
| Feb 1, 2023 | Third Rock Ventures III, L.P. | 10% Owner | Sell | 388,642 | $9.23 | $3.59M0.7% OS | 4,998,933 |
| Jan 31, 2023 | Third Rock Ventures III, L.P. | 10% Owner | Sell | 50,000 | $9.02 | $451.0K | 5,073,933 |
| Jan 26, 2023 | Third Rock Ventures III, L.P. | 10% Owner | Sell | 150,000 | $9.25 | $1.39M | 5,173,933 |
Showing 1–50 of 74
1 / 2
VYGR Insider Buying Activity
The following table shows recent insider purchases of Voyager Therapeutics, Inc. (VYGR) stock reported via SEC Form 4 filings.
No insider buying activity found for VYGR in the last 12 months.
VYGR Insider Selling Activity
The following table shows recent insider sales of Voyager Therapeutics, Inc. (VYGR) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | Carter Todd Alfred | officer: Chief Scientific Officer | Sell | 4,174 | $3.76 | $15.7K | 145,718 |
| Feb 26, 2026 | Jorgensen Nathan D. | officer: Chief Financial Officer | Sell | 4,668 | $3.77 | $17.6K | 151,416 |
| Feb 26, 2026 | Sandrock Alfred | director, officer: President and CEO | Sell | 14,197 | $3.79 | $53.8K | 484,060 |
| Feb 26, 2026 | Swartz Robin | officer: COO & CBO | Sell | 6,458 | $3.77 | $24.3K | 199,738 |
| Feb 18, 2026 | Carter Todd Alfred | Chief Scientific Officer | Sell | 3,301 | $3.44 | $11.4K | 0 |
| Feb 18, 2026 | Sandrock Alfred | President and CEO | Sell | 11,732 | $3.41 | $40.0K | 0 |
| Feb 18, 2026 | Swartz Robin | COO & CBO | Sell | 3,882 | $3.44 | $13.4K | 0 |
| Feb 11, 2026 | Carter Todd Alfred | officer: Chief Scientific Officer | Sell | 3,525 | $3.85 | $13.6K | 153,193 |
| Feb 11, 2026 | Sandrock Alfred | director, officer: President and CEO | Sell | 12,192 | $3.78 | $46.1K | 509,989 |
| Feb 11, 2026 | Swartz Robin | officer: COO & CBO | Sell | 4,569 | $3.85 | $17.6K | 210,078 |
| Oct 7, 2025 | Jorgensen Nathan D. | Chief Financial Officer | Sell | 7,666 | $4.78 | $36.6K | 123,834 |
| Aug 20, 2025 | Ferguson Toby | Chief Medical Officer | Sell | 19,000 | $3.73 | $70.9K | 138,914 |
| Apr 4, 2025 | Ferguson Toby | Chief Medical Officer | Sell | 10,086 | $3.43 | $34.6K | 157,914 |
| Apr 4, 2025 | Sandrock Alfred | President and CEO | Sell | 10,885 | $3.43 | $37.3K | 430,931 |
| Feb 24, 2025 | Carter Todd Alfred | Chief Scientific Officer | Sell | 3,305 | $4.26 | $14.1K | 77,718 |
| Feb 24, 2025 | Sandrock Alfred | President and CEO | Sell | 11,702 | $4.24 | $49.6K | 296,816 |
| Feb 24, 2025 | Swartz Robin | COO & CBO | Sell | 3,894 | $4.25 | $16.5K | 98,397 |
| Feb 12, 2025 | Carter Todd Alfred | Chief Scientific Officer | Sell | 5,413 | $4.45 | $24.1K | 81,023 |
| Feb 12, 2025 | Fahey Sandell Jacquelyn | Chief Legal Officer | Sell | 4,358 | $4.45 | $19.4K | 81,643 |
| Feb 12, 2025 | Sandrock Alfred | President & CEO | Sell | 16,644 | $4.45 | $74.1K | 308,518 |
| Feb 12, 2025 | Swartz Robin | COO & CBO | Sell | 6,950 | $4.45 | $30.9K | 102,291 |
| Jan 15, 2025 | Carter Todd Alfred | Chief Scientific Officer | Sell | 1,191 | $5.13 | $6.1K | 86,436 |
| Jan 15, 2025 | Swartz Robin | COO & CBO | Sell | 3,087 | $5.09 | $15.7K | 109,241 |
| Dec 26, 2024 | Swartz Robin | COO&CBO | Sell | 6,500 | $5.65 | $36.7K | 112,328 |
| Oct 3, 2024 | Fahey Sandell Jacquelyn | Chief Legal Officer | Sell | 5,999 | $5.82 | $34.9K | 86,001 |
| Apr 3, 2024 | Sandrock Alfred | President and CEO | Sell | 12,115 | $9.86 | $119.5K | 322,839 |
| Apr 3, 2024 | Swartz Robin | Chief Operating Officer | Sell | 1,357 | $9.88 | $13.4K | 117,004 |
| Feb 22, 2024 | Carter Todd Alfred | Chief Scientific Officer | Sell | 3,967 | $7.50 | $29.8K | 90,992 |
| Feb 22, 2024 | PFREUNDSCHUH PETER P. | Chief Financial Officer | Sell | 3,764 | $7.46 | $28.1K | 175,669 |
| Feb 22, 2024 | Sandrock Alfred | President and CEO | Sell | 13,033 | $7.46 | $97.2K | 334,954 |
| Feb 22, 2024 | Swartz Robin | Chief Operating Officer | Sell | 3,966 | $7.45 | $29.5K | 118,361 |
| Jan 19, 2024 | Carter Todd Alfred | Chief Scientific Officer | Sell | 1,266 | $7.18 | $9.1K | 53,094 |
| Jan 19, 2024 | Swartz Robin | Chief Operating Officer | Sell | 2,543 | $7.15 | $18.2K | 72,327 |
| Oct 5, 2023 | PFREUNDSCHUH PETER P. | Chief Financial Officer | Sell | 13,567 | $6.99 | $94.8K | 149,433 |
| Sep 18, 2023 | Carter Todd Alfred | Chief Scientific Officer | Sell | 10,500 | $8.16 | $85.7K | 54,360 |
| Jul 10, 2023 | Carter Todd Alfred | Chief Scientific Officer | Sell | 5,500 | $10.80 | $59.4K | 59,860 |
| Jul 5, 2023 | Carter Todd Alfred | Chief Scientific Officer | Sell | 5,000 | $11.41 | $57.0K | 65,360 |
| Apr 5, 2023 | Sandrock Alfred | President and CEO | Sell | 7,437 | $7.83 | $58.2K | 214,618 |
| Apr 5, 2023 | Swartz Robin | Chief Operating Officer | Sell | 1,259 | $7.83 | $9.9K | 71,617 |
| Mar 22, 2023 | Carter Todd Alfred | Chief Scientific Officer | Sell | 2,193 | $7.76 | $17.0K | 65,360 |
| Mar 22, 2023 | Hesslein Robert W. | Senior VP & General Counsel | Sell | 4,410 | $7.76 | $34.2K | 102,200 |
| Mar 22, 2023 | Swartz Robin | Chief Operating Officer | Sell | 3,654 | $7.76 | $28.4K | 72,876 |
| Mar 17, 2023 | Swartz Robin | Chief Operating Officer | Sell | 15,373 | $8.20 | $126.1K | 76,530 |
| Feb 22, 2023 | Carter Todd Alfred | Chief Scientific Officer | Sell | 738 | $7.45 | $5.5K | 67,553 |
| Feb 22, 2023 | Hesslein Robert W. | Senior VP & General Counsel | Sell | 3,297 | $7.45 | $24.6K | 106,610 |
| Feb 15, 2023 | Carter Todd Alfred | Chief Scientific Officer | Sell | 797 | $7.67 | $6.1K | 34,291 |
| Feb 15, 2023 | Hesslein Robert W. | Senior VP & General Counsel | Sell | 2,868 | $7.67 | $22.0K | 109,907 |
| Feb 1, 2023 | Third Rock Ventures III, L.P. | 10% Owner | Sell | 388,642 | $9.23 | $3.59M0.7% OS | 4,998,933 |
| Jan 31, 2023 | Third Rock Ventures III, L.P. | 10% Owner | Sell | 50,000 | $9.02 | $451.0K | 5,073,933 |
| Jan 26, 2023 | Third Rock Ventures III, L.P. | 10% Owner | Sell | 150,000 | $9.25 | $1.39M | 5,173,933 |
VYGR Insiders
Similar Stocks to VYGR
VRTX
Vertex Pharmaceuticals Incorporated
$429.47+0.81%
$111.71B
REGN
Regeneron Pharmaceuticals, Inc.
$734.06-1.39%
$77.87B
ALNY
Alnylam Pharmaceuticals, Inc.
$303.44-1.64%
$41.24B
INSM
Insmed Incorporated
$135.11-0.64%
$30.79B
RVMD
Revolution Medicines, Inc.
$144.62+9.92%
$29.51B
UTHR
United Therapeutics Corporation
$566.69+0.03%
$25.13B
MRNA
Moderna, Inc.
$47.16-3.17%
$21.42B
RPRX
Royalty Pharma plc
$49.40-0.50%
$21.20B